Loncastuximab tesirine

Loncastuximab tesirine is a human cluster of differentiation 19 (CD19) -directed antibody-drug conjugate (ADC) . The antibody portion is Loncastuximab (HY-P99711), and the drug-linker conjugate for ADC is Tesirine (HY-128952) . Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma[1][2].

Product Specifications

CAS Number

[1879918-31-6]

Product Name Alternative

Loncastuximab tesirine-lpyl; ADCT-402

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Apoptosis

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/loncastuximab-tesirine.html

Purity

99.37

Solubility

10 mM in DMSO

Smiles

[Loncastuximabtesirine]

Molecular Weight

147000 (average)

References & Citations

[1]Nikoleta Sachini, et al. Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma. Blood. 2021.|[2]Zammarchi F, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018 Mar 8;131 (10) :1094-1105.